CARDIOVASCULAR OUTCOMES WITH FINERENONE ACCORDING TO STATUS OF GLYCEMIA AT BASELINE AND PRIOR TREATMENT WITH NEWER ANTIDIABETICS AMONG PATIENTS WITH TYPE 2 DIABETES MELLITUS

Dimitrios Patoulias,Alexandra Katsimardou,Konstantinos Stavropoulos,Konstantinos Imprialos,Konstantinos Koutsampasopoulos,Aristi Boulmpou,Maria Toumpourleka,Fotios Siskos,Christodoulos Papadopoulos,Michael Doumas

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY（2022）

引用 0|浏览1

暂无评分

摘要

Finerenone provides significant cardiovascular benefit for patients with T2DM, especially for those being obese, while the level of glycemia or treatment with newer antidiabetics at baseline does not seem to affect the observed cardio-protective action.

查看译文

关键词

glycemia status baseline,newer antidiabetics,diabetes mellitus,finerenone

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要